EANS-News: Intercell AG Vivalis SA shareholders approved the proposed merger
of equals to create Valneva SE
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information
Wien (euro adhoc) - Nantes (France), Vienna (Austria), March 7, 2013 - Intercell
AG (VSE: ICLL) and Vivalis SA (NYSE Euronext: VLS) today announced that the
Extraordinary General Meeting of both companies approved the proposed merger of
equals between Intercell AG and Vivalis SA to create Valneva SE.
In today's Extraordinary Shareholders' Meeting of Vivalis held in Nantes,
France, all resolutions were approved by its shareholders. A majority of 99.1%
of the represented share capital voted in favor of the merger to create Valneva
SE, a biotech leader in vaccines and antibodies. A total of approximately 70% of
the outstanding share capital of Vivalis SA was represented in the shareholders
meeting.
As previously announced, Intercell's shareholder approved the proposed merger
with Vivalis SA with a majority of 97.4% of the represented share capital.
Following the approvals of the both shareholders the merger is now only subject
to completion of certain administrative steps and is expected to close in May
2013. Subject to the approval of the French market authorities, Valneva SE will
launch a EUR 40 million capital increase shortly after the completion of the
Merger.
Thomas Lingelbach, future President and Chief Executive Officer of Valneva and
Franck Grimaud, future President and Chief Business Officer commented: "We are
excited about the broad approval of the merger by our shareholders and are now
heading towards closing in May 2013. Valneva will be a European biotech leader
in vaccines and antibodies with complementing talents and capabilities, a broad
portfolio of product candidates, diversified revenues and enhanced financial
strength to fund its future growth."
Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime
stockmarkets: official market: Wien
language: English